Cinética y capacidad neutralizante de los anticuerpos homólogos y ...

Referencias Bibliográficas
223. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced
severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks.
Rev Panam Salud Publica 2002;11(4):223-7.
224. Rico-Hesse R. Dengue Virus Evolution and Virulence Models. CID 2007;44:1462-
6.
225. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, et al.
Failure of secondary infection with American genotype dengue 2 to cause dengue
haemorrhagic fever. Lancet 1999;354(9188):1431-4.
226. Messer WB, Vitarana UT, Sivananthan K, Elvtigala J, Preethimala LD, Ramesh R,
et al. Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic
dengue hemorrhagic fever. Am J Trop Med Hyg 2002;66(6):765-73.
227. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. Emergence and
global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 2003;9(7):800-9.
228. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, et al.
Failure of secondary infection with American genotype dengue 2 to cause dengue
haemorrhagic fever [see comments]. Lancet 1999;354(9188):1431-4.
229. Cologna R, Armstrong PM, Rico-Hesse R. Selection for virulent dengue viruses
occurs in humans and mosquitoes. J Virol 2005;79(2):853-9.
230. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv Virus Res
2003;59:315-41.
231. Imrie A., Meeks J., Gurary A., Sukhbaatar M., Truong TT., Cropp B. C, et al.
Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 2007;
Winter 20(4):672-5.
232. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al.
Relationship of Preexisting Dengue Virus (DV) Neutralizing Antibody Levels to Viremia
and Severity of Disease in a Prospective Cohort Study of DV Infection in Thailand. J Infect
Dis 2004;189(6):990-1000.
233. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent
enhancement of dengue virus growth in human monocytes as a risk factor for dengue
hemorrhagic fever. Am J Trop Med Hyg 1989;40(4):444-51.
234. Halstead S, Russ SB. Subclinical Japanese Encephalitis. II. Antibody responses of
American to single exposure to JE virus. Am J Hyg 1962;75:202-211.
235. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by
passively transferred antibody. J Infect Dis 1979;140(4):527-33.
236. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, et al.
Differing influences of virus burden and immune activation on disease severity in
secondary dengue-3 virus infections. J Infect Dis 2002;185(9):1213-21.
237. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibodydependent
enhancement of infection upregulates the production of anti-inflammatory
cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine
production, in THP-1 cells. J Gen Virol 2007;88(Pt 2):365-75.
238. Cummings DA, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic effects of
antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci U S A
2005;102(42):15259-64.
239. Halstead SB, Suaya JA, Shepard DS. The burden of dengue infection. Lancet
2007;369(9571):1410-1.
134